Benjamin A. Schiffman

Array ( [id] => 19923012 [patent_doc_number] => 12297283 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-13 [patent_title] => Fc binding fragments comprising an OX40 antigen-binding site [patent_app_type] => utility [patent_app_number] => 17/259714 [patent_app_country] => US [patent_app_date] => 2019-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 17 [patent_no_of_words] => 40574 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17259714 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17082099 [patent_doc_number] => 20210277105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => TREATING ULCERATIVE COLITIS WITH BRAZIKUMAB [patent_app_type] => utility [patent_app_number] => 17/259448 [patent_app_country] => US [patent_app_date] => 2019-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13252 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17259448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19090989 [patent_doc_number] => 11952419 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-09 [patent_title] => Reagents and methods for treating cancer and autoimmune disease [patent_app_type] => utility [patent_app_number] => 17/057429 [patent_app_country] => US [patent_app_date] => 2019-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 34864 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17057429 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17111837 [patent_doc_number] => 20210292434 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => NOVEL STABLE HIGH-CONCENTRATION FORMULATION FOR ANTI-FXIa ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/257828 [patent_app_country] => US [patent_app_date] => 2019-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17257828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17082113 [patent_doc_number] => 20210277119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/256917 [patent_app_country] => US [patent_app_date] => 2019-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 96124 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -145 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17256917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15342671 [patent_doc_number] => 20200009227 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => COMPOSITIONS AND METHODS OF CONTROLLING EXPRESSION OF THERMOGENIN (UCP-1) IN SKELETAL MUSCLES [patent_app_type] => utility [patent_app_number] => 16/502509 [patent_app_country] => US [patent_app_date] => 2019-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16658 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16502509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16570704 [patent_doc_number] => 20210009710 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING LRIT2 INHIBITOR AS ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 17/041220 [patent_app_country] => US [patent_app_date] => 2019-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3654 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17041220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17022323 [patent_doc_number] => 20210246194 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => Optimized gp41-Binding Molecules and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/055805 [patent_app_country] => US [patent_app_date] => 2019-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33233 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16791745 [patent_doc_number] => 20210121562 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER [patent_app_type] => utility [patent_app_number] => 17/043537 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15147 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17043537 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16582878 [patent_doc_number] => 20210017280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => CONSTRUCTS TRAGETING CD22 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/043352 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66311 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17043352 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16584113 [patent_doc_number] => 20210018515 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => BIOMARKER COMBINATION FOR IDENTIFICATION OF "AT-RISK" SUBJECTS FOR AKI [patent_app_type] => utility [patent_app_number] => 17/040016 [patent_app_country] => US [patent_app_date] => 2019-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17040016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19651262 [patent_doc_number] => 12173030 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-24 [patent_title] => CAR-Treg-based therapies for treating neurodegenerative diseases [patent_app_type] => utility [patent_app_number] => 17/041835 [patent_app_country] => US [patent_app_date] => 2019-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 14 [patent_no_of_words] => 9528 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17041835 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16870103 [patent_doc_number] => 20210163570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => ENGINEERED CELLS, T CELL IMMUNE MODULATING ANTIBODIES AND METHODS FOR USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/980742 [patent_app_country] => US [patent_app_date] => 2019-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16980742 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16628783 [patent_doc_number] => 20210047436 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => ANTI- POLYSIALIC ACID ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/980354 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16980354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18434341 [patent_doc_number] => 20230181635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => ANTI-CXCR4 ANTIBODY COMBINED WITH ACTIVATED AND EXPANDED NATURAL KILLER CELLS FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/979968 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19354 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16979968 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170397 [patent_doc_number] => 20210324067 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2021-10-21 [patent_title] => COMBINATION THERAPY FOR CARDIOVASCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 16/978660 [patent_app_country] => US [patent_app_date] => 2019-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -102 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16978660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170397 [patent_doc_number] => 20210324067 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2021-10-21 [patent_title] => COMBINATION THERAPY FOR CARDIOVASCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 16/978660 [patent_app_country] => US [patent_app_date] => 2019-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -102 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16978660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16582852 [patent_doc_number] => 20210017254 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => Antibody Purification [patent_app_type] => utility [patent_app_number] => 16/975994 [patent_app_country] => US [patent_app_date] => 2019-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18023 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16975994 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16990078 [patent_doc_number] => 20210228498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER [patent_app_type] => utility [patent_app_number] => 16/967549 [patent_app_country] => US [patent_app_date] => 2019-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13778 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16967549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19778571 [patent_doc_number] => 12227595 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => Anti-renalase antibodies for the treatment and prevention of diseases and disorders [patent_app_type] => utility [patent_app_number] => 16/958960 [patent_app_country] => US [patent_app_date] => 2018-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 36 [patent_no_of_words] => 34082 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16958960 [rel_patent_id] =>[rel_patent_doc_number] =>)